Combined dietary intervention and exercise: The available information on the role of combined lifestyle interventions (hypocaloric diets plus exercise) in patients with NAFLD is much more extensive, with several randomized, controlled trials showing significant benefit with this comprehensive approach. Again, the overall reduction in liver fat reported in most of these trials has been strongly correlated with the amount of weight loss.

Once given FDA approval, the Senseonics Eversence System will be the fourth CGMS available in the U.S. It was submitted to the FDA for premarket approval last October, supported by data from a 90-patient pivotal trial of the device. The trial followed adults with type 1 or type 2 diabetes over 90 days of CGM sensor wearing. This is an implantable CGM system that is currently approved in Europe. The sensor sits just under your skin and can stay there for anywhere from 90-180 days.

Diet may play a major role in magnesium and its association to type 2 diabetes.

Researchers found that the Alzheimer’s gene ApoE4 could be linked to type 3 diabetes. The Apolipoprotein E (APOE) gene is one of the strongest genetic risk factors for Alzheimer’s disease. Diabetes and impaired insulin signaling in the brain are linked to the development of Alzheimer’s disease. This study shows how …

Diabetes has long been divided into type 1 and type 2. But a third type has entered the mix — and we aren't diagnosing it correctly.

SGLT-2 inhibitors were associated with more acute renal failure reports than other diabetes medications.

New study suggests improvement in quality of life and obesity seen with liraglutide compared with placebo.

Sensor-augmented therapy can diminish hypoglycemia with the low-glucose suspend feature.

OptiScanner is the first-of-its-kind bedside blood monitoring platform that provides plasma-based, automated monitoring of ICU patients’ glucose levels. The OptiScanner 5000 directly measures plasma glucose levels using an integrated blood centrifuge and spectrometer to help avoid dangerous glycemic variations and assist clinicians in achieving the right level of glucose control.

The FDA has approved an auto-injector and new formulation of a once-weekly treatment for type 2 diabetes from AstraZeneca. Bydureon BCise offers a single-dose auto-injector for adults with type 2 diabetes. Bydureon BCise features a unique continuous-release microsphere technology delivery system that provides consistent levels of the product’s active ingredient, exenatide. The new formulation has shown the ability to reduce blood sugar levels alongside weight loss, despite not being a weight loss medication.